From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
CCUS
CHIP
Clonal hematopoiesis
Genetic testing
ICUS
Myeloid neoplasm
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
10
02
2019
revised:
22
06
2019
accepted:
02
07
2019
pubmed:
12
8
2019
medline:
25
1
2020
entrez:
12
8
2019
Statut:
ppublish
Résumé
Clonal hematopoiesis (CH) as defined by the presence of somatic mutations in genes associated with myeloid neoplasms (MN) is common in healthy elderly individuals and does not necessarily constitute a premalignant state. Several acronyms (idiopathic cytopenia of undetermined significance [ICUS], clonal cytopenia of undetermined significance [CCUS], CH of indeterminate potential [CHIP]) related to CH have been coined to describe patients who do not meet the diagnostic criteria for other hematologic disorders. CHIP carries an annual progression rate to MN of 0.5-1.0% as well as an increased risk of cardiovascular mortality and development of therapy-related MN in patients with solid tumors. Further studies on the natural history of ICUS, CCUS, and CHIP and to assess the risk for progression to MN are needed. Herein, we review the current understanding and clinical significance of these conditions to guide physicians in the interpretation of genetic testing results in various clinical settings.
Identifiants
pubmed: 31400824
pii: S0268-960X(19)30012-8
doi: 10.1016/j.blre.2019.100587
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100587Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK102792
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.